Silence Therapeutics (NASDAQ:SLN) Price Target Lowered to $75.00 at HC Wainwright

Silence Therapeutics (NASDAQ:SLN) had its price objective decreased by HC Wainwright from $80.00 to $75.00 in a research note released on Friday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Other research analysts have also issued reports about the stock. Chardan Capital reissued a buy rating and set a $26.00 price objective on shares of Silence Therapeutics in a report on Thursday, August 17th. Morgan Stanley restated an overweight rating and issued a $20.00 price target on shares of Silence Therapeutics in a research report on Monday, July 24th.

Silence Therapeutics Price Performance

SLN opened at $9.50 on Friday. The company has a fifty day simple moving average of $9.01 and a 200 day simple moving average of $7.30. The firm has a market cap of $284.32 million, a price-to-earnings ratio of -6.55 and a beta of 0.62. Silence Therapeutics has a twelve month low of $4.55 and a twelve month high of $17.99. The company has a current ratio of 4.86, a quick ratio of 4.21 and a debt-to-equity ratio of 0.01.

Hedge Funds Weigh In On Silence Therapeutics

Several hedge funds have recently made changes to their positions in the business. Lombard Odier Asset Management USA Corp increased its position in shares of Silence Therapeutics by 4.1% in the second quarter. Lombard Odier Asset Management USA Corp now owns 4,120,416 shares of the company’s stock worth $18,668,000 after acquiring an additional 161,315 shares in the last quarter. Lombard Odier Asset Management Europe Ltd increased its position in shares of Silence Therapeutics by 3.7% in the second quarter. Lombard Odier Asset Management Europe Ltd now owns 3,415,360 shares of the company’s stock worth $18,784,000 after acquiring an additional 121,955 shares in the last quarter. Artal Group S.A. increased its position in shares of Silence Therapeutics by 236.6% in the second quarter. Artal Group S.A. now owns 1,700,000 shares of the company’s stock worth $9,350,000 after acquiring an additional 1,194,926 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Silence Therapeutics by 27.1% in the first quarter. Goldman Sachs Group Inc. now owns 965,815 shares of the company’s stock worth $18,350,000 after acquiring an additional 205,815 shares in the last quarter. Finally, M28 Capital Management LP increased its position in shares of Silence Therapeutics by 149.3% in the second quarter. M28 Capital Management LP now owns 363,800 shares of the company’s stock worth $2,001,000 after acquiring an additional 217,900 shares in the last quarter. Institutional investors and hedge funds own 64.27% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's mRNAi GOLD GalNAc Oligonucleotide Discovery platform that is used to target specific disease-associated genes in the liver.